Lanean...
18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
BACKGROUND: (18)F‐flutemetamol uptake by brain tissue, measured by positron emission tomography (PET), is accepted by regulatory agencies like the Food and Drug Administration (FDA) and the European Medicine Agencies (EMA) for assessing amyloid load in people with dementia. Its added value is mainly...
Gorde:
| Argitaratua izan da: | Cochrane Database Syst Rev |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
John Wiley & Sons, Ltd
2017
|
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6486287/ https://ncbi.nlm.nih.gov/pubmed/29164602 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012884 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|